Cellceutix completes enrollment in Phase II for ulcerative proctitis

Cellceutix Corp. (OTCQB:CTIX) completed enrollment of 17 patients with mild to moderate ulcerative proctitis or proctosigmoiditis in a Phase II trial evaluating once-daily 50, 100 and 200 mg brilacidin via retention enema for 6 weeks. The company plans to report interim data from the trial at the Drug Discovery and Therapy World Congress in Boston in July.

The open-label trial’s primary endpoint is clinical remission as measured by the Modified Mayo Disease Activity Index (MMDAI). Secondary endpoints include change in MMDAI score, quality of life (QOL), safety and pharmacokinetics...